- Home
- APVO vs CDT Comparison
APVO vs CDT Comparison
Compare APVO & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- CDT
- Stock Information
- Founded
- APVO 2016
- CDT 2019
- Country
- APVO United States
- CDT United States
- Employees
- APVO N/A
- CDT N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- CDT Health Care
- Exchange
- APVO Nasdaq
- CDT Nasdaq
- Market Cap
- APVO 5.4M
- CDT 5.2M
- IPO Year
- APVO N/A
- CDT N/A
- Fundamental
- Price
- APVO $1.38
- CDT $0.75
- Analyst Decision
- APVO Strong Buy
- CDT
- Analyst Count
- APVO 1
- CDT 0
- Target Price
- APVO $296.00
- CDT N/A
- AVG Volume (30 Days)
- APVO 1.2M
- CDT 1.4M
- Earning Date
- APVO 05-07-2025
- CDT 05-13-2025
- Dividend Yield
- APVO N/A
- CDT N/A
- EPS Growth
- APVO N/A
- CDT N/A
- EPS
- APVO N/A
- CDT N/A
- Revenue
- APVO N/A
- CDT N/A
- Revenue This Year
- APVO N/A
- CDT N/A
- Revenue Next Year
- APVO N/A
- CDT N/A
- P/E Ratio
- APVO N/A
- CDT N/A
- Revenue Growth
- APVO N/A
- CDT N/A
- 52 Week Low
- APVO $0.94
- CDT $0.65
- 52 Week High
- APVO $180.19
- CDT $350.00
- Technical
- Relative Strength Index (RSI)
- APVO 31.11
- CDT 33.47
- Support Level
- APVO $0.94
- CDT $0.76
- Resistance Level
- APVO $2.64
- CDT $1.05
- Average True Range (ATR)
- APVO 0.45
- CDT 0.14
- MACD
- APVO -0.07
- CDT 0.08
- Stochastic Oscillator
- APVO 16.42
- CDT 20.46
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.